Systematic assessment of growth factor treatment on biochemical and biomechanical properties of engineered articular cartilage constructs  by Elder, B.D. & Athanasiou, K.A.
Osteoarthritis and Cartilage (2009) 17, 114e123
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2008.05.006
International
Cartilage
Repair
SocietySystematic assessment of growth factor treatment on biochemical and
biomechanical properties of engineered articular cartilage constructs1
B. D. Elder M.S. and K. A. Athanasiou Ph.D., P.E.*
Department of Bioengineering, Rice University, MS 142, P.O. Box 1892, Houston, TX 77251-1892, USA
Summary
Objective: To determine the effects of bone morphogenetic protein-2 (BMP-2), insulin-like growth factor (IGF-I), and transforming growth
factor-b1 (TGF-b1) on the biochemical and biomechanical properties of engineered articular cartilage constructs under serum-free conditions.
Methods: A scaffoldless approach for tissue engineering, the self-assembly process, was employed. The study consisted of two phases. In the
ﬁrst phase, the effects of BMP-2, IGF-I, and TGF-b1, at two concentrations and two dosage frequencies each were assessed on construct
biochemical and biomechanical properties. In phase II, the effects of growth factor combination treatments were determined. Compressive
and tensile mechanical properties, glycosaminoglycan (GAG) and collagen content, histology for GAG and collagen, and immunohistochem-
istry (IHC) for collagen types I and II were assessed.
Results: In phase I, BMP-2 and IGF-I treatment resulted in signiﬁcant, >1-fold increases in aggregate modulus, accompanied by increases in
GAG production. Additionally, TGF-b1 treatment resulted in signiﬁcant, w1-fold increases in both aggregate modulus and tensile modulus,
with corresponding increases in GAG and collagen content. In phase II, combined treatment with BMP-2 and IGF-I increased aggregate
modulus and GAG content further than either growth factor alone, while TGF-b1 treatment alone remained the only treatment to also enhance
tensile properties and collagen content.
Discussion: This study determined systematically the effects of multiple growth factor treatments under serum-free conditions, and is the ﬁrst
to demonstrate signiﬁcant increases in both compressive and tensile biomechanical properties as a result of growth factor treatment. These
ﬁndings are exciting as coupling growth factor application with the self-assembly process resulted in tissue engineered constructs with
functional properties approaching native cartilage values.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage has a limited ability for self-repair, and
injuries to articular cartilage result in the formation of
mechanically inferior ﬁbrocartilage1. Since current clinical
treatments are limited, tissue engineering is a promising
strategy for articular cartilage regeneration.
To alleviate some of the potential issues associated with
scaffold use, our lab has developed and employed
a scaffoldless process for tissue engineering, called the
self-assembly process2e4. Using this process, the goal is
to create engineered constructs with biochemical and
biomechanical properties approaching those of native
tissue. Growth factor application appears to be a promising
approach for enhancing these properties.1Grant support: National Institute of Arthritis and Musculoskeletal
and Skin Disease, R01 AR053286.
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114Previous studies5,6 systematically assessed the effects of
several growth factors at different concentrations on
chondrocyte-seeded PGA scaffolds, and indicated that
treatment with bone morphogenetic protein-2 (BMP-2) and in-
sulin-like growth factor (IGF-I) enhanced glycosaminoglycan
(GAG) production, while transforming growth factor-b1
(TGF-b1) enhanced collagen production. However, these
studies employed fetal bovine serum (FBS) in the medium,
potentially confounding the effects of exogenous growth
factor application. Also, a prior study by Ng et al.7 indicated
beneﬁcial effects from temporal application of IGF-I and
TGF-b1.
Although many studies have demonstrated beneﬁcial
effects of growth factor application, no studies have system-
atically assessed the effects of growth factors alone and in
combination under serum-free conditions. Furthermore, no
studies have examined growth factor effects on both
compressive and tensile properties. The objective of this
study was to determine the effects of growth factor applica-
tion on the biomechanical and biochemical properties of
self-assembled articular cartilage constructs. This study
utilized a 2-phase approach to determine the effects of
single growth factor treatments followed by the determina-
tion of the effects of combined growth factor treatments.
Based on the results of prior studies5,6,8e10, in phase I, it
was hypothesized that BMP-2 and IGF-I treatment would
115Osteoarthritis and Cartilage Vol. 17, No. 1enhance compressive properties by increasing GAG
production, and TGF-b1 treatment would enhance both
compressive and tensile properties by increasing GAG
production and collagen production, respectively. It was
further hypothesized that growth factor concentration and
dosage frequency would have signiﬁcant effects on
construct biochemical and biomechanical properties, based
on prior work11,12. In phase II, it was hypothesized that
combined growth factor treatment would have beneﬁcial ef-
fects on construct properties, by increasing biochemical and
biomechanical properties further than any growth factor
alone. To test these hypotheses, three experiments were
performed in phase I and one experiment was performed
in phase II. In phase I, BMP-2, IGF-I, and TGF-b1 were
all assessed at two concentrations and two dosage
frequencies each, with the best treatment for each growth
factor selected for use in phase II. In phase II, the growth
factor treatments selected from phase I were assessed in
combinations of two and three.MethodsCHONDROCYTE ISOLATION AND SEEDINGChondrocytes were obtained from the distal femur of wk-old male cal-
ves13e15 (Research 87, Boston, MA), and digested with collagenase type
2 (Worthington, Lakewood, NJ). Each leg yielded roughly 150 million chon-
drocytes, and animal variability was reduced by pooling cells from ﬁve legs
of different animals to yield a mixture of chondrocytes for each study (see
descriptions below). The pooled cells were counted on a hemocytometer,Fig. 1. Schematic diagram indicating experimental designs of phases I a
for each individual growth factor separately (blocked by growth factor). T
Phase II assessed the effects of each growth factor indand viability >90% was found using a trypan blue exclusion test.
Chondrocytes were frozen in culture medium supplemented with 20%
FBS (Biowhittaker) and 10% dimethyl sulfoxide (DMSO) at 80C for 3
days before use in phase I, and for 3 wks before use in phase II. After
thawing, viability remained greater than 85%. A polysulfone die
consisting of 5 mm dia. 10 mm long cylindrical prongs was used to con-
struct each agarose mold. Sterile, molten 2% agarose was introduced into
a well ﬁtted with the polysulfone die. The agarose was allowed to gel at
room temperature for 60 min, and two exchanges of culture medium
were used to completely saturate the agarose well with culture medium
by the time of cell seeding. To each well, 5.5 106 cells in 100 ml of culture
medium were added. The cells self-assembled within 24 h in the agarose
wells and were maintained in the same well for t¼ 10 days; t¼ 0 was de-
ﬁned as 24 h after seeding. The culture medium was Dulbecco’s Modiﬁed
Eagle Medium (DMEM) with 4.5 g/L-glucose and L-glutamine (Biowhittaker/
Cambrex, Walkersville, MD), 100 nM dexamethasone (Sigma, St. Louis,
MO), 1% fungizone/penicillin/streptomycin (Biowhittaker), 1% ITSþ
(BD Scientiﬁc, Franklin Lakes, NJ), 50 mg/mL ascorbate-2-phosphate,
40 mg/mL L-proline, and 100 mg/mL sodium pyruvate (Fisher Scientiﬁc,
Pittsburgh, PA).PHASE I: INDIVIDUAL GROWTH FACTOR EFFECTSThis phase included three separate studies to assess the individual ef-
fects of BMP-2, IGF-I and TGF-b1 at different concentrations and dosage fre-
quencies. All growth factors were obtained from Peprotech Inc. (Rocky Hill,
NJ), and were applied in the culture medium. For each growth factor, the ef-
fects of two concentrations (low and high) and two dosage frequencies were
assessed, with separate no growth factor controls for each study, yielding
a total of ﬁve treatment groups for each growth factor study (Fig. 1). The con-
centrations used were 10 and 100 ng/ml for BMP-2 and IGF-I, and 10 and
30 ng/ml for TGF-b1, selected from prior studies5,6. The dosage regimens
were 2 wks continuous application followed by 2 wks of no growth factor
(continuous), or growth factor application only during the ﬁrst and third wk
of culture (wk rotation), which were chosen based on pilot studies and cur-
rent ongoing work in our group as well as adapted from prior studies using
intermittent growth factor application by Lieb et al.11,12nd II. The experimental design depicted in phase I was carried out
he best treatment for each growth factor was selected for phase II.
ividually and in all combinations of two and three.
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were removed from conﬁnement in 5 mm dia. agarose wells and transferred
to individual 2% agarose coated wells of a 48-well culture plate for the re-
mainder of the study. Per construct, 500 ml of medium was changed daily,
and all constructs were assessed at t¼ 4 wks. The ‘‘best’’ treatment for
each growth factor was selected, using a functionality index as described be-
low, for use in phase II.PHASE II: GROWTH FACTOR COMBINATION EFFECTSOne treatment for each growth factor was selected from phase I to be
compared individually, as well as in combinations of two and three in phase
II (Fig. 1). The speciﬁc application treatments selected were 10 ng/ml con-
tinuous BMP-2, 10 ng/ml wk rotation IGF-I, and 30 ng/ml continuous TGF-
b1. As in phase I, constructs were unconﬁned from agarose wells at t¼ 10
days, and transferred to individual 2% agarose coated wells of a 48-well
culture plate for the remainder of the study. Again, 500 ml of medium per
construct was changed daily, and all constructs were assessed at
t¼ 4 wks.HISTOLOGY AND IMMUNOHISTOCHEMISTRYSamples were frozen and sectioned at 14 mm. Safranin-O and fast
green staining were used to examine GAG distribution16,17. Picrosirius
red was used for qualitative examination of collagen content. A von Kossa
stain was used to assess for mineralization. Slides were also processed
with immunohistochemistry (IHC) to test for the presence of collagen
types I, II, and X. After ﬁxing in chilled acetone, the slides were rinsed
with IHC buffer (Biogenex), quenched of peroxidase activity with hydrogen
peroxide/methanol, and blocked with horse serum (Vectastain ABC kit,
Vector Laboratories, Burlingame, CA). The slides were then incubated
with either mouse anti-collagen type I (Accurate Chemicals, Westbury,
NY), rabbit anti-collagen type II (Cedarlane Labs, Burlington, NC), or rab-
bit anti-collagen X (Abcam Inc., Cambridge, MA) antibodies. The second-
ary antibody (anti-mouse or anti-rabbit IgG, Vectastain ABC kit) was
applied, and color was developed using the Vectastain ABC reagent
and DAB (Vectastain kit).QUANTITATIVE BIOCHEMISTRYSamples were frozen overnight and lyophilized for 72 h, followed by re-
suspension in 0.8 mL of 0.05 M acetic acid with 0.5 M NaCl and 0.1 mL of
a 10 mg/mL pepsin solution (Sigma) at 4C for 72 h. Next, 0.1 mL of 10
Tris buffered saline (TBS) was added along with 0.1 mL pancreatic
elastase and mixed at 4C overnight. From this digest, total DNA content
was measured by Picogreen Cell Proliferation Assay Kit (Molecular Probes,
Eugene, OR). Total sulfated GAG was then quantiﬁed using the Blyscan
Glycosaminoglycan Assay kit (Biocolor), based on 1,9-dimethylmethylene
blue binding18,19. After being hydrolyzed by 2 N NaOH for 20 min at
110C, samples were assayed for total collagen content by a chloramine-T
hydroxyproline assay20.INDENTATION TESTINGSamples were evaluated with an indentation apparatus21. A step mass of
0.7 g (0.007 N) was applied with a 1 mm ﬂat-ended, porous indenter tip, and
specimens were allowed to creep until equilibrium, as described elsewhere2.
Preliminary estimations of the aggregate modulus of the samples were ob-
tained using the analytical solution for the axisymmetric Boussinesq problem
with Papkovich potential functions22,23. The aggregate modulus (HA), perme-
ability, and Poisson’s ratio of the samples were then determined using the
linear biphasic theory24.TENSILE TESTINGTensile tests were performed using a uniaxial materials testing system
(Instron Model 5565, Canton, MA) with a 50 N load cell as described pre-
viously25. Brieﬂy, samples were cut into a dog-bone shape with a 1-mm-
long gauge length. Samples were attached to paper tabs for gripping
with cyanoacrylate glue outside of the gauge length. The 1-mm-long sec-
tions were pulled at a constant strain rate of 0.01 s1. Stressestrain
curves were created from the loadedisplacement curve and the cross-
sectional area of each sample, and Young’s modulus (EY) was
calculated from the linear region of each stressestrain curve.FUNCTIONALITY INDEX (FI)A functionality index (Eq. (1)) was used to determine the ‘‘best’’ treat-
ment condition for each growth factor in phase I, for use in phase II. The
index was only used as a selection tool within each experiment, without
making comparisons among experiments. It was weighted using normal-
ized collagen and GAG content, tensile stiffness, and creep indentation
compressive stiffness. The index served as a quantiﬁed comparison be-
tween the properties of the engineered constructs and native tissue. In
the functionality index, G represents GAG/WW, C represents collagen/
WW, ET represents tensile modulus, and EC represents compressive stiff-
ness (aggregate modulus). The subscripts nat and sac are used to denote
native and self-assembled construct values, respectively. Using immature
bovine cartilage explants, native tissue values were 5% and 15% for
GAG/WW and collagen/WW, respectively, and 213 kPa and 12.1 MPa for
EC and ET, respectively. Although different weights may be afforded to
each component of the FI, they are equally weighted in this study. Since
the eventual goal of our tissue engineering approach is in vivo construct im-
plantation, as cartilage experiences both compressive and tensile loading
in the joint, these properties are equally weighted. Furthermore, the bio-
chemical characteristics are equally important as constructs with biochem-
ical characteristics divergent from native tissue may present problems in
construct integration with native tissue. However, due to the ﬂexibility of
the FI, the exact weights can easily be modiﬁed based on the results of fu-
ture studies.
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ð1ÞSTATISTICAL ANALYSISAll samples were assessed biochemically and biomechanically (n¼ 6 or
7). In each phase, a single factor ANOVA was used to analyze the samples,
and a Fisher least signiﬁcant difference (LSD) post hoc test was used when
warranted. Signiﬁcance was deﬁned as P< 0.05.ResultsGROSS APPEARANCE AND HISTOLOGYConstruct diameter was approximately 6 mm in all stud-
ies. In phase I, BMP-2 at all concentrations and dosages
increased construct wet weight (WW) and thickness
slightly, as demonstrated in Table I. IGF-I treatment led
to a slightly decreased construct WW, with no differences
in construct thickness, as shown in Table II. Finally, treat-
ment with TGF-b1 resulted in a concentration dependent
decrease in construct WW and thickness, as indicated in
Table III. In phase II, there were no differences in con-
struct WW or thickness among any of the treatment
groups (Table IV). In all studies, constructs stained posi-
tive for collagen and GAG throughout their thickness
(Fig. 2), and based on IHC, collagen II was expressed
throughout each construct, with no collagen I production.
Similar images can be observed in our previous work4. Ad-
ditionally, no constructs demonstrated mineralization and
no chondrocyte hypertrophy was noted with BMP-2
treatment.QUANTITATIVE BIOCHEMISTRYIn phase I, there were no differences in cells/construct
among the different treatment groups in the BMP-2 study
(Table I). Treatment with 10 ng/ml continuous BMP-2 led
to the greatest increase in GAG/WW, although all BMP-2
treatments signiﬁcantly increased GAG/WW [Fig. 3(c)].
Table I
Properties of constructs treated with BMP-2 in phase I
Group WW (mg) Thickness (mm) Total cells (106) FI
Control 21.8 2.4 0.67 0.04 4.6 0.5 0.75 0.18
100 ng/ml Continuous 23.7 1.8 0.71 0.07 5.3 0.3 0.94 0.06*
100 ng/ml Wk Rotat. 22.6 1.9 0.71 0.04 4.8 0.9 0.96 0.08*
10 ng/ml Continuous 23.3 2.0 0.73 0.07 4.4 1.0 0.97 0.10*
10 ng/ml Wk Rotat. 23.8 1.3 0.72 0.04 4.8 0.3 0.92 0.06*
Wk Rotat., 2-wk rotation dosage; Col., total collagen.
*Signiﬁcantly different from control.
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the treatment groups [Fig. 3(d)]. In the IGF-I study, there
were no differences in cells/construct among any of the
treatment groups (Table II). All IGF-I treatments signiﬁcantly
increased GAG/WW, with the exception of 10 ng/ml contin-
uous treatment [Fig. 4(c)]. There were no differences in
collagen/WW among any of the treatment groups
[Fig. 4(d)]. In the TGF-b1 study, 30 ng/ml treatment led to
an approximately 14% increase in cells/construct (Table III).
Additionally, 30 ng/ml TGF-b1, at either continuous or
2 wk rotation dosages, signiﬁcantly increased both colla-
gen/WW and GAG/WW [Fig. 5(c and d)].
In phase II, there were no differences in cells/construct
among any of the treatment groups (Table IV). All growth
factor treatments signiﬁcantly increased GAG/WW,
although combined BMP-2 and IGF-I treatment led to the
greatest increase in GAG/WW [Fig. 6(c)]. However, both
treatments with TGF-b1 alone and combined application
of all three growth factors signiﬁcantly increased collagen/
WW [Fig. 6(d)].MECHANICAL EVALUATIONIn phase I, all BMP-2 treatments signiﬁcantly increased
aggregate modulus, although BMP-2 at 10 ng/ml continu-
ous application led to the greatest increase [Fig. 3(a)].
There were no differences in Poisson’s ratio or permeability
noted among the different groups, with ranges of 0.15e0.28
and 4.1 1014e1.2 1013, respectively. Furthermore,
there were no differences in Young’s modulus among any
of the treatment groups in the BMP-2 study [Fig. 3(b)]. In
the IGF-I study, all IGF-I treatments except for 10 ng/ml
continuous signiﬁcantly increased aggregate modulus,
while application at 10 ng/ml wk rotation led to the greatest
increase in aggregate modulus [Fig. 4(a)]. There were no
differences in Poisson’s ratio or permeability noted among
the different groups, with ranges of 0.19e0.26 and
8.0 1014e1.2 1013, respectively. Additionally, thereTable I
Properties of constructs treate
Group WW (mg) Thickness
Control 25.7 1.0 0.74
100 ng/ml Continuous 24.5 1.4 0.65
100 ng/ml Wk Rotat. 22.7 1.6* 0.71
10 ng/ml Continuous 23.2 1.7* 0.75
10 ng/ml Wk Rotat. 24.1 1.9 0.75
Wk Rotat., 2-wk rotation dosage; Col., total collagen.
*Signiﬁcantly different from control.were no differences in Young’s modulus among any of
the treatment groups in the IGF-I study [Fig. 4(b)]. In the
TGF-b1 study, only 30 ng/ml continuous treatment signiﬁ-
cantly increased aggregate modulus [Fig. 5(a)]. However,
both TGF-b1 treatments at 30 ng/ml exhibited a signiﬁcant
increase in Young’s modulus [Fig. 5(b)]. There were no dif-
ferences among the treatment groups for Poisson’s ratio
and permeability, with ranges of 0.09e0.22 and
2.3 1014e7.2 1014, respectively.
In phase II, all three individual growth factor treatments
signiﬁcantly increased aggregate modulus [Fig. 6(a)], repli-
cating the results of phase I. However, combined BMP-2
and IGF-I treatment led to the greatest enhancement of
aggregate modulus. Only individual application of TGF-b1
signiﬁcantly increased Young’s modulus [Fig. 6(b)]. There
were no differences in Poisson’s ratio or permeability
among the treatment groups, with ranges of 0.09e0.26
and 5.1 1014e1.3 1013, respectively.Discussion
The objective of this study was to assess systematically
the effects of growth factors on the biochemical and biome-
chanical properties of self-assembled articular cartilage
constructs. The study utilized a two-phase approach to
determine the effects of different growth factors, concentra-
tions, and dosage frequencies, as well as to examine the
effects of growth factor combination treatment. This
approach allowed for a methodical growth factor examina-
tion under serum-free conditions. To the best of our knowl-
edge, this study is the ﬁrst to demonstrate signiﬁcant
increases in both compressive and tensile biomechanical
properties as a result of growth factor treatment.
In phase I, all BMP-2 treatments led to signiﬁcant
increases in construct compressive stiffness and GAG/
WW. The greatest enhancement was observed with 2 wkI
d with IGF-I in phase I
(mm) Total cells (106) FI
0.06 5.2 0.6 0.59 0.19
0.08 5.3 0.7 0.93 0.12*
0.09 5.0 0.4 0.92 0.14*
0.10 4.6 0.6 0.78 0.19*
0.12 5.0 0.3 0.96 0.08*
Table III
Properties of constructs treated with TGF-b1 in phase I
Group WW (mg) Thickness (mm) Total cells (106) FI
Control 24.9 2.8 0.88 0.14 5.7 0.3 0.60 0.08
30 ng/ml Continuous 12.6 0.7* 0.57 0.06* 6.6 0.4* 0.82 0.07*
30 ng/ml Wk Rotat. 13.9 0.6* 0.57 0.02* 6.5 0.8* 0.81 0.14*
10 ng/ml Continuous 17.8 1.3* 0.64 0.09* 5.7 0.4 0.62 0.07
10 ng/ml Wk Rotat. 17.9 4.6* 0.76 0.17 5.8 0.8 0.55 0.06
Wk Rotat., 2-wk rotation dosage; Col., total collagen.
*Signiﬁcantly different from control.
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increase in compressive stiffness. Despite the increased
compressive properties, no increases in tensile properties
or collagen/WW were noted for any of the treatment groups.
These results supported our hypothesis that BMP-2 would
only increase the compressive properties of the constructs
by increasing the GAG/WW, as increased GAG production
without changes in collagen synthesis has previously been
observed with BMP-2 treatment6,26. BMP-2 treatment of
2 wk continuous dosage at 10 ng/ml was selected for use
in phase II as it demonstrated the greatest increase in the
functionality index.
Similarly, in phase I, all IGF-I treatments except for 10 ng/
ml continuous application signiﬁcantly increased construct
compressive stiffness and GAG/WW. However, the great-
est increase was observed with the wk rotation dosage at
10 ng/ml, with a 122% increase in compressive stiffness.
As with BMP-2 treatment, no increases in tensile properties
or collagen/WW were observed for any of the treatment
groups. These results supported our hypothesis that IGF-I
would increase only the compressive properties of the
constructs by increasing the GAG/WW, as previous studies
demonstrated enhanced GAG production without changes
in collagen synthesis from IGF-I treatment in both tissue
engineered constructs and explants5,27,28. IGF-I treatment
of wk rotation dosage at 10 ng/ml was selected for use in
phase II as it demonstrated the greatest increase in the
functionality index.
Finally, in phase I, 30 ng/ml TGF-b1 treatment, at either
dosage frequency, signiﬁcantly increased tensile stiffness
and collagen/WW, as well as GAG/WW. However, only
30 ng/ml TGF-b1 treatment at the 2 wk continuous dosage
signiﬁcantly increased compressive stiffness. These results
demonstrate that the enhancement of compressive proper-
ties likely requires a lag period, as suggested previously7,Table I
Phase II construc
Group WW (mg) Thickne
Control 13.3 1.3 0.45
BMP-2 15.0 1.6 0.55
IGF-I 13.3 3.1 0.55
TGF-b1 14.5 1.6 0.58
BMP-2þ IGF-I 16.7 1.3* 0.59
BMP-2þ TGF-b1 14.9 1.4 0.57
IGF-Iþ TGF-b1 14.2 1.4 0.57
BMP-2þ IGF-Iþ TGF-b1 13.0 1.3 0.53
Col., total collagen.
*Signiﬁcantly different from control.following TGF-b1 treatment; both 30 ng/ml treatments in-
creased GAG/WW, but only the 2 wk continuous application,
with 2 wks between cessation of growth factor treatment and
construct evaluation, demonstrated an increase in compres-
sive stiffness. It is likely that the increased lag time is required
to incorporate and organize the GAG and collagen into the
ECM7. Based on these results, 2 wk continuous TGF-b1
treatment at 30 ng/ml was selected for use in phase II as it
demonstrated the greatest increase in the functionality index,
and was the only treatment in phase I that increased both
compressive and tensile properties. This result supported
our hypothesis that TGF-b1 treatment would increase both
compressive and tensile properties by increasing both
GAG and collagen content, respectively. Additionally this
ﬁnding corresponds with previous work that has demon-
strated that TGF-b1 treatment increases collagen synthesis
or gene expression5,29e31, while TGF-b1 treatment only un-
der serum-free conditions increases proteoglycan
synthesis29.
In phase I, the different dosage frequencies had profound
effects on the biochemical and biomechanical properties of
the constructs. For example, 10 ng/ml IGF-I applied at the
2 wk continuous dosage signiﬁcantly increased compres-
sive stiffness and GAG/WW, while 10 ng/ml IGF-I applied
at the wk rotation dosage had no effect on compressive
stiffness and GAG/WW. Additionally, as described above,
only 30 ng/ml TGF-b1 treatment at the 2 wk continuous
dosage increased the compressive stiffness. A possible
explanation is that different dosages may mimic temporal
patterns of growth factor expression during wound healing32
as well as during chondrogenesis, as reviewed by Goldring
et al.33
TGF-b1 and the combination of BMP-2 and IGF-I were
identiﬁed as the winners in terms of construct functionality
in this study. These results were primarily obtained in phaseV
t properties
ss (mm) Total cells (106) FI
0.09 5.6 0.5 0.53 0.06
0.06 5.2 0.4 0.76 0.07*
0.05 5.7 0.9 0.73 0.12*
0.05 5.5 0.3 0.72 0.04*
0.05 5.9 0.4 0.80 0.08*
0.04 5.8 0.6 0.66 0.02*
0.06 5.5 0.3 0.59 0.04
0.08 6.1 0.4 0.70 0.05
Fig. 2. Photomicrographs of collagen and GAG staining for no growth factor control constructs, BMP-2þ IGF-I treated constructs, and TGF-b1
treated constructs. 10 original magniﬁcation.
119Osteoarthritis and Cartilage Vol. 17, No. 1II, where BMP-2, IGF-I, and TGF-b1 were applied at the
selected conditions from phase I in combinations of one,
two, or three. Combined BMP-2 and IGF-I treatment had
beneﬁcial effects, demonstrating the greatest increase in
aggregate modulus (119%), accompanied by the greatestFig. 3. Biomechanical and biochemical properties of BMP-2 treated co
(a) aggregate modulus with no effect on (b) Young’s modulus. Likewis
no effect on (d) collagen/WW. Columns and error bars represent means
signiﬁcantly differeincrease in GAG/WW (54%). However, as with the use of
these growth factors individually, there was no difference
in tensile properties or collagen/WW. As in phase I, only
treatment with TGF-b1 alone led to a signiﬁcant increase
in tensile properties and collagen/WW. There wasnstructs in phase I. All BMP-2 treatments signiﬁcantly increased
e, all BMP-2 treatments signiﬁcantly increased (c) GAG/WW with
and standard deviations. Groups denoted by different letters are
nt (P< 0.05).
Fig. 4. Biomechanical and biochemical properties of IGF-I treated constructs in phase I. All IGF-I treatments, except 10 ng/ml continuous,
signiﬁcantly increased (a) aggregate modulus with no effect on (b) Young’s modulus. Likewise, all IGF-I treatments, except 10 ng/ml contin-
uous, signiﬁcantly increased (c) GAG/WW with no effect on (d) collagen/WW. Columns and error bars represent means and standard devi-
ations. Groups denoted by different letters are signiﬁcantly different (P< 0.05).
Fig. 5. Biomechanical and biochemical properties of TGF-b1 treated constructs in phase I. TGF-b1 treatment at 30 ng/ml and 2-wk continuous
dosage signiﬁcantly increased (a) aggregate modulus and (b) Young’s modulus, with corresponding increases in (c) GAG/WW and (d) colla-
gen/WW. Columns and error bars represent means and standard deviations. Groups denoted by different letters are signiﬁcantly different
(P< 0.05).
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Fig. 6. Biomechanical and biochemical properties of constructs in phase II. Combined treatment with BMP-2 and IGF-I led to the greatest
enhancement of aggregate modulus and GAG/WW, while TGF-b1 alone was the only treatment to enhance both compressive and tensile
stiffness. (a) Aggregate modulus, (b) Young’s modulus, (c) GAG/WW and (d) collagen/WW. Columns and error bars represent means and
standard deviations. Groups denoted by different letters are signiﬁcantly different (P< 0.05).
121Osteoarthritis and Cartilage Vol. 17, No. 1a disparity in values obtained for the individual growth factor
treatments between phases I and II, likely as a result of dif-
ferent donor tissue from which the cells were isolated. How-
ever, although the values for the properties of the control
constructs vary between the phases, similar percent in-
creases in properties are observed for the individual growth
factors in each phase.
It is also interesting to note that combining TGF-b1 with
either of the other growth factors did not have additive or
synergistic effects, negating the increased compressive
and tensile stiffness observed with TGF-b1 treatment
alone. This result agrees with prior work by Blunk et al.5
which noted that combined TGF-b1 and IGF-I treatment
decreased GAG and collagen fractions. Additionally,
TGF-b1 has been shown to regulate the autocrine/para-
crine axis of IGF-I34, and it is likely that combined growth
factor treatment may alter these intracellular pathways, po-
tentially leading to the reduced effects observed in this
study. Prior work by Suzuki et al.35 also supports our re-
sults, as it was demonstrated that BMP-2 signal transduc-
tion was inhibited by application of TGF-b1. However, it is
possible that there is a concentration-dependence of our
results; for example, if TGF-b1 was applied at much higher
or lower concentrations than used in the manuscript, IGF-I
and BMP-2 may have different responses than what was
reported in this study.It is important to note that our results differ from several
prior growth factors studies5,6 which have utilized culture
medium containing FBS. This medium already contains
growth factors, potentially confounding the effects of addi-
tional growth factor application. In this study, we utilized
serum-free medium to control for any confounding from
the presence of FBS in the medium and to enable us
to look solely at the effects of the growth factor supple-
mentation. The use of serum-free medium may explain
some of the differences between our results and those
of prior studies. Additionally, the self-assembly process
may modulate some of the effects of growth factors differ-
ently. For example, Gooch et al.6 found that treatment
with BMP-2 at 100 ng/ml led to the presence of hypertro-
phic chondrocytes; however, we found no differences in
chondrocyte morphology nor any other histological proper-
ties. Furthermore, it has previously been shown that
growth factor application at higher concentrations signiﬁ-
cantly increases construct WW5,6. We did not observe
this WW increase, and in fact found that TGF-b1 treat-
ment actually decreased the construct WW. It is possible
that these responses are due to the combined effects of
FBS and supplemental growth factors, and that the use
of growth factors in serum-free conditions mitigates the
hypertrophic response at the concentrations used in this
study.
122 B. D. Elder and K. A. Athanasiou: Systematic growth factor treatmentAlthough multiple studies have examined the effects of
various growth factors on monolayer, explant, and
engineered construct gene expression and biochemical
properties, this study systematically assessed the effects
of different growth factors, concentrations, dosages, and
combinations, leading to construct biochemical and biome-
chanical properties in the range of native tissue values.
Since most other investigations of engineered cartilage
have not achieved the biochemical and biomechanical
properties found in this study in only 4 wks, the results
presented here likely are due to the combination of the
self-assembling process, serum-free media, and the
selected growth factor regimens. Only treatment with
TGF-b1 was found to enhance both the compressive and
tensile properties of engineered constructs, while com-
bined treatment with BMP-2 and IGF-I led to adjunctive en-
hancement of construct compressive stiffness and GAG
content. As previous studies have demonstrated beneﬁcial
effects of combined growth factor treatment and direct
compression14,36, future studies should assess the effects
of these growth factor treatments when combined with
mechanical stimulation, such as hydrostatic pressure and
direct compression.Conﬂict of interest
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